Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 18

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
 194,285,714 340,000 350,000 350,000

2)
A $ 35,000

3)
$ 75,900 4,328

No
actions were taken by any of the parties to enforce the terms of the Agreement.

On
April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a)
Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note
shall not reflect such return

b)
As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued
by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between
Zander and Regen on June 23, 2015 (“ License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and
license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic
use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on
December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement
and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto.

Zander
and Regen are under common control.

On
January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“ BST”) whereby Regen Biopharma,
Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis
for $ 5,000

The
Company agreed that in addition to the base rent of $ 5,000

BST
Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

$ 63,948 15

$ 15,000 10

$ 25,000 10

$ 10,000 10

$ 4,700 10

$ 4,500 10

Zander
Therapeutics, Inc. and the Company are under common control.